Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 4/2016

01-04-2016 | Symposium-in-writing paper

Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?

Authors: Beatriz Sanchez-Correa, Carmen Campos, Alejandra Pera, Juan M. Bergua, Maria Jose Arcos, Helena Bañas, Javier G. Casado, Sara Morgado, Esther Duran, Rafael Solana, Raquel Tarazona

Published in: Cancer Immunology, Immunotherapy | Issue 4/2016

Login to get access

Abstract

Several age-associated changes in natural killer (NK) cell phenotype have been reported that contribute to the defective NK cell response observed in elderly patients. A remodelling of the NK cell compartment occurs in the elderly with a reduction in the output of immature CD56bright cells and an accumulation of highly differentiated CD56dim NK cells. Acute myeloid leukaemia (AML) is generally a disease of older adults. NK cells in AML patients show diminished expression of several activating receptors that contribute to impaired NK cell function and, in consequence, to AML blast escape from NK cell immunosurveillance. In AML patients, phenotypic changes in NK cells have been correlated with disease progression and survival. NK cell-based immunotherapy has emerged as a possibility for the treatment of AML patients. The understanding of age-associated alterations in NK cells is therefore necessary to define adequate therapeutic strategies in older AML patients.
Literature
1.
Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904–910CrossRefPubMed
2.
Almeida-Oliveira A, Smith-Carvalho M, Porto LC, Cardoso-Oliveira J, Ribeiro AS, Falcao RR, Abdelhay E, Bouzas LF, Thuler LC, Ornellas MH, Diamond HR (2011) Age-related changes in natural killer cell receptors from childhood through old age. Hum Immunol 72:319–329CrossRefPubMed
3.
4.
5.
Balducci L, Yates J (2000) General guidelines for the management of older patients with cancer. Oncology (Williston Park) 14:221–227
6.
Borrego F, Alonso MC, Galiani MD, Carracedo J, Ramirez R, Ostos B, Pena J, Solana R (1999) NK phenotypic markers and IL2 response in NK cells from elderly people. Exp Gerontol 34:253–265CrossRefPubMed
7.
Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A (2003) Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198:557–567CrossRefPubMedPubMedCentral
8.
Braciak TA, Wildenhain S, Roskopf CC, Schubert IA, Fey GH, Jacob U, Hopfner KP, Oduncu FS (2013) NK cells from an AML patient have recovered in remission and reached comparable cytolytic activity to that of a healthy monozygotic twin mediated by the single-chain triplebody SPM-2. J Transl Med 11:289CrossRefPubMedPubMedCentral
9.
10.
11.
Campos C, Pera A, Lopez-Fernandez I, Alonso C, Tarazona R, Solana R (2014) Proinflammatory status influences NK cells subsets in the elderly. Immunol Lett 162:298–302CrossRefPubMed
12.
Campos C, Pera A, Sanchez-Correa B, Alonso C, Lopez-Fernandez I, Morgado S, Tarazona R, Solana R (2014) Effect of age and CMV on NK cell subpopulations. Exp Gerontol 54:130–137CrossRefPubMed
13.
14.
Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99:3661–3667CrossRefPubMed
15.
Curti A, Ruggeri L, D’Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM (2011) Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118:3273–3279CrossRefPubMed
16.
de Andrade LF, Smyth MJ, Martinet L (2014) DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins. Immunol Cell Biol 92:237–244CrossRefPubMed
17.
18.
Di Lorenzo G, Balistreri CR, Candore G, Cigna D, Colombo A, Romano GC, Colucci AT, Gervasi F, Listi F, Potestio M, Caruso C (1999) Granulocyte and natural killer activity in the elderly. Mech Ageing Dev 108:25–38CrossRefPubMed
19.
Erba HP (2015) Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leuk Res 39:183–191CrossRefPubMed
20.
Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA (2003) Biology and clinical impact of human natural killer cells. Int J Hematol 78:7–17CrossRefPubMed
21.
Fauriat C, Just-Landi S, Mallet F, Arnoulet C, Sainty D, Olive D, Costello RT (2007) Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109:323–330CrossRefPubMed
22.
Gayoso I, Sanchez-Correa B, Campos C, Alonso C, Pera A, Casado JG, Morgado S, Tarazona R, Solana R (2011) Immunosenescence of human natural killer cells. J Innate Immun 3:337–343CrossRefPubMed
23.
Glienke W, Esser R, Priesner C, Suerth JD, Schambach A, Wels WS, Grez M, Kloess S, Arseniev L, Koehl U (2015) Advantages and applications of CAR-expressing natural killer cells. Front Pharmacol 6:21CrossRefPubMedPubMedCentral
24.
Hayhoe RP, Henson SM, Akbar AN, Palmer DB (2010) Variation of human natural killer cell phenotypes with age: identification of a unique KLRG1-negative subset. Hum Immunol 71:676–681CrossRefPubMed
25.
Hazeldine J, Lord JM (2013) The impact of ageing on natural killer cell function and potential consequences for health in older adults. Ageing Res Rev 12:1069–1078CrossRefPubMedPubMedCentral
26.
Herberman RB, Nunn ME, Holden HT, Lavrin DH (1975) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16:230–239CrossRefPubMed
27.
28.
Hudspeth K, Silva-Santos B, Mavilio D (2013) Natural cytotoxicity receptors: broader expression patterns and functions in innate and adaptive immune cells. Front Immunol 4:69CrossRefPubMedPubMedCentral
29.
Jabbour EJ, Estey E, Kantarjian HM (2006) Adult acute myeloid leukemia. Mayo Clin Proc 81:247–260CrossRefPubMed
30.
31.
Khaznadar Z, Henry G, Setterblad N, Agaugue S, Raffoux E, Boissel N, Dombret H, Toubert A, Dulphy N (2014) Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. Eur J Immunol 44:3068–3080CrossRefPubMed
32.
Kiessling R, Klein E, Pross H, Wigzell H (1975) “Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5:117–121CrossRefPubMed
33.
Kiessling R, Klein E, Wigzell H (1975) “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 5:112–117CrossRefPubMed
34.
Klingemann H (2015) Challenges of cancer therapy with natural killer cells. Cytotherapy 17:245–249CrossRefPubMed
35.
Koch J, Steinle A, Watzl C, Mandelboim O (2013) Activating natural cytotoxicity receptors of natural killer cells in cancer and infection. Trends Immunol 34:182–191CrossRefPubMed
36.
Krakow EF, Bergeron J, Lachance S, Roy DC, Delisle JS (2014) Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Rev 28:249–261CrossRefPubMed
37.
Krishnaraj R (1997) Senescence and cytokines modulate the NK cell expression. Mech Ageing Dev 96:89–101CrossRefPubMed
38.
39.
Le Garff-Tavernier M, Beziat V, Decocq J, Siguret V, Gandjbakhch F, Pautas E, Debre P, Merle-Beral H, Vieillard V (2010) Human NK cells display major phenotypic and functional changes over the life span. Aging Cell 9:527–535CrossRefPubMed
40.
Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B, Subklewe M (2014) Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML. Leuk Res 38:964–969CrossRefPubMed
41.
Lion E, Willemen Y, Berneman ZN, Van TV, Smits EL (2012) Natural killer cell immune escape in acute myeloid leukemia. Leukemia 26:2019–2026CrossRefPubMed
42.
Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237–244CrossRefPubMed
43.
Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7:329–339CrossRefPubMed
44.
Locatelli F, Moretta F, Brescia L, Merli P (2014) Natural killer cells in the treatment of high-risk acute leukaemia. Semin Immunol 26:173–179CrossRefPubMed
45.
Lopez-Botet M, Muntasell A, Vilches C (2014) The CD94/NKG2C + NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection. Semin Immunol 26:145–151CrossRefPubMed
46.
Lutz CT, Moore MB, Bradley S, Shelton BJ, Lutgendorf SK (2005) Reciprocal age related change in natural killer cell receptors for MHC class I. Mech Ageing Dev 126:722–731CrossRefPubMedPubMedCentral
47.
Mariani E, Mariani AR, Meneghetti A, Tarozzi A, Cocco L, Facchini A (1998) Age-dependent decreases of NK cell phosphoinositide turnover during spontaneous but not Fc-mediated cytolytic activity. Int Immunol 10:981–989CrossRefPubMed
48.
Mariani E, Meneghetti A, Neri S, Ravaglia G, Forti P, Cattini L, Facchini A (2002) Chemokine production by natural killer cells from nonagenarians. Eur J Immunol 32:1524–1529CrossRefPubMed
49.
Miller JS (2013) Therapeutic applications: natural killer cells in the clinic. Hematol Am Soc Hematol Educ Prog 2013:247–253CrossRef
50.
Milush JM, Lopez-Verges S, York VA, Deeks SG, Martin JN, Hecht FM, Lanier LL, Nixon DF (2013) CD56negCD16(+) NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology 10:158CrossRefPubMedPubMedCentral
51.
Mocchegiani E, Malavolta M (2004) NK and NKT cell functions in immunosenescence. Aging Cell 3:177–184CrossRefPubMed
52.
Montaldo E, Del ZG, Della CM, Mingari MC, Moretta A, De MA, Moretta L (2013) Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A 83:702–713CrossRefPubMed
53.
Montaldo E, Vacca P, Moretta L, Mingari MC (2014) Development of human natural killer cells and other innate lymphoid cells. Semin Immunol 26:107–113CrossRefPubMed
54.
Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197–223CrossRefPubMed
55.
Moretta L, Montaldo E, Vacca P, Del ZG, Moretta F, Merli P, Locatelli F, Mingari MC (2014) Human natural killer cells: origin, receptors, function, and clinical applications. Int Arch Allergy Immunol 164:253–264CrossRefPubMed
56.
Muntasell A, Vilches C, Angulo A, Lopez-Botet M (2013) Adaptive reconfiguration of the human NK-cell compartment in response to cytomegalovirus: a different perspective of the host-pathogen interaction. Eur J Immunol 43:1133–1141CrossRefPubMed
57.
Murasko DM, Jiang J (2005) Response of aged mice to primary virus infections. Immunol Rev 205:285–296CrossRefPubMed
58.
Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, Cosman D, De LG, Wodnar-Filipowicz A (2005) Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 105:3615–3622CrossRefPubMed
59.
Oyer JL, Igarashi RY, Kulikowski AR, Colosimo DA, Solh MM, Zakari A, Khaled YA, Altomare DA, Copik AJ (2015) Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach. Biol Blood Marrow Transplant 21:632–639CrossRefPubMed
60.
61.
Pawelec G, Solana R, Remarque E, Mariani E (1998) Impact of aging on innate immunity. J Leukoc Biol 64:703–712PubMed
62.
Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, Falco M, Lanino E, Pierri I, Zambello R, Bacigalupo A, Mingari MC, Moretta A, Moretta L (2005) Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105:2066–2073CrossRefPubMed
63.
Rambaldi A, Biagi E, Bonini C, Biondi A, Introna M (2015) Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches. Leukemia 29:1–10CrossRefPubMed
64.
65.
Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D, Luo X, Cooley S, Verneris M, Walcheck B, Miller J (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 121:3599–3608CrossRefPubMedPubMedCentral
66.
Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, Steinle A (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102:1389–1396CrossRefPubMed
67.
Sanchez CJ, Le TT, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello RT (2011) Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother 60:1–13CrossRefPubMed
68.
Sanchez-Correa B, Bergua JM, Campos C, Gayoso I, Arcos MJ, Banas H, Morgado S, Casado JG, Solana R, Tarazona R (2013) Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine 61:885–891CrossRefPubMed
69.
Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R (2012) Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 90:109–115CrossRefPubMed
70.
Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, Bengochea ML, Duran E, Solana R, Tarazona R (2011) Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 60:1195–1205CrossRefPubMed
71.
Schmeel FC, Schmeel LC, Gast SM, Schmidt-Wolf IG (2014) Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci 15:14632–14648CrossRefPubMedPubMedCentral
72.
Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, Phillips JH (1996) DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4:573–581CrossRefPubMed
73.
Siegler U, Kalberer CP, Nowbakht P, Sendelov S, Meyer-Monard S, Wodnar-Filipowicz A (2005) Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice. Leukemia 19:2215–2222CrossRefPubMed
74.
Solana R, Alonso MC, Pena J (1999) Natural killer cells in healthy aging. Exp Gerontol 34:435–443CrossRefPubMed
75.
Solana R, Campos C, Pera A, Tarazona R (2014) Shaping of NK cell subsets by aging. Curr Opin Immunol 29:56–61CrossRefPubMed
76.
77.
78.
Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T (2012) Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol 24:331–341CrossRefPubMed
79.
Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie AN, Mebius RE, Powrie F, Vivier E (2013) Innate lymphoid cells–a proposal for uniform nomenclature. Nat Rev Immunol 13:145–149CrossRefPubMed
80.
Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K (2014) Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 99:836–847CrossRefPubMedPubMedCentral
81.
Szczepanski MJ, Szajnik M, Welsh A, Foon KA, Whiteside TL, Boyiadzis M (2010) Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol Immunother 59:73–79CrossRefPubMedPubMedCentral
82.
Tarazona R, Casado JG, Delarosa O, Torre-Cisneros J, Villanueva JL, Sanchez B, Galiani MD, Gonzalez R, Solana R, Pena J (2002) Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 22:176–183CrossRefPubMed
83.
Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L (2008) Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9:486–494CrossRefPubMed
84.
Verheyden S, Demanet C (2008) NK cell receptors and their ligands in leukemia. Leukemia 22:249–257CrossRefPubMed
85.
Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS (2013) Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition. Clin Cancer Res 19:3844–3855CrossRefPubMedPubMedCentral
86.
Zafirova B, Wensveen FM, Gulin M, Polic B (2011) Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci 68:3519–3529CrossRefPubMedPubMedCentral
87.
Zhou Q, Gil-Krzewska A, Peruzzi G, Borrego F (2013) Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clin Exp Immunol 173:131–139CrossRefPubMedPubMedCentral
Metadata
Title
Natural killer cell immunosenescence in acute myeloid leukaemia patients: new targets for immunotherapeutic strategies?
Authors
Beatriz Sanchez-Correa
Carmen Campos
Alejandra Pera
Juan M. Bergua
Maria Jose Arcos
Helena Bañas
Javier G. Casado
Sara Morgado
Esther Duran
Rafael Solana
Raquel Tarazona
Publication date
01-04-2016
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 4/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-015-1720-6

Other articles of this Issue 4/2016

Cancer Immunology, Immunotherapy 4/2016 Go to the issue

Original Article

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node

Original Article

A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor–dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2

Symposium-in-writing paper

Selection and expansion of natural killer cells for NK cell-based immunotherapy

Symposium-in-writing paper

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

Symposium-in-writing paper

Age-related changes in natural killer cell repertoires: impact on NK cell function and immune surveillance

Symposium-in-Writing Paper

CD57 in human natural killer cells and T-lymphocytes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits